Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Takeaways - MDSpire

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

Share

1

Lenz Therapeutics received FDA approval for Vizz, an eye drop solution for treating presbyopia in adults.
2

Vizz improves near vision within 30 minutes and effects last up to 10 hours.
3

The treatment works by contracting the iris sphincter muscle to create a pinhole effect, enhancing depth of focus.
4

Clinical trials CLARITY 1, 2, and 3 demonstrated Vizz's safety and efficacy with mild, transient adverse events.
5

Commercial availability of Vizz is expected by mid-Q4 2025, with samples anticipated as early as October 2025.